Quick Takeaways
- Ayrton Capital LLC filed SCHEDULE 13G for ReShape Lifesciences Inc. Common stock, par value $0.001 per share (RSLS).
- Disclosed ownership: 5.7%.
- Date of event: 31 Mar 2025.
Ayrton Capital LLC - 31 Mar 2025 SCHEDULE 13G Report for ReShape Lifesciences Inc. Common stock, par value $0.001 per share (RSLS)
- Filing Manager
- Ayrton Capital LLC
- Reporting Manager
- Ayrton Capital LLC
- Symbol
- RSLS
- Shares outstanding
- 3,502,627 shares
- Disclosed Ownership
- 200,000 shares
- Ownership
- 5.7%
- Form type
- SCHEDULE 13G
- Filing time
- 14 May 2025, 14:59:01 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Ayrton Capital LLC disclosed 5.7% ownership in ReShape Lifesciences Inc. Common stock, par value $0.001 per share (RSLS) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 May 2025, 14:59.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Ayrton Capital LLC | 5.7% | 200,000 | 200,000 | 0 | /s/ Waqas Khatri | Waqas Khatri / Managing Member | |
| Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B | 5.7% | 200,000 | 200,000 | 0 | /s/ Waqas Khatri | Waqas Khatri / Director | |
| Waqas Khatri | 5.7% | 200,000 | 200,000 | 0 | /s/ Waqas Khatri | Waqas Khatri |